ARCH Venture Management, LLC
13F Reported Value
ⓘ$1.1B
Holdings
12
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
ARCH Venture Management, LLC disclosed 12 positions worth $1.1B in its Form 13F-HR for Q2 2026, led by $PBLS (Parabilis Medicines, Inc.) at 15.9% of the equity portfolio, followed by $BEAM and $RAPP. During the quarter the fund opened 3 new positions and exited 1 — including a new stake in $PBLS and a full exit from $FIXX. The portfolio is most concentrated in Healthcare (99.2% of disclosed assets). All figures are sourced directly from ARCH Venture Management, LLC’s Form 13F-HR filing with the SEC under CIK 1274403.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$175.5M6,412,780 sh - 34.2#2,357
Quality
$155.8M4,540,132 sh - —
Quality
$155.4M3,728,738 sh - —
Quality
$136.6M6,294,951 sh - —
Quality
$129.9M7,091,557 sh - 38.2
Quality
$129.4M12,694,163 sh - 10.3
Quality
$123.0M4,120,053 sh - 9.3
Quality
$45.5M3,247,162 sh - —
Quality
$32.8M1,944,426 sh - 40.5
Quality
$8.4M217,834 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Parabilis Medicines, Inc.$PBLS | — | $175.5M | 6,412,780 |
 Beam Therapeutics Inc.$BEAM | 34.2#2,357 | $155.8M | 4,540,132 |
 Rapport Therapeutics, Inc.$RAPP | — | $155.4M | 3,728,738 |
 Seaport Therapeutics, Inc.$SPTX | — | $136.6M | 6,294,951 |
 Erasca, Inc.$ERAS | — | $129.9M | 7,091,557 |
 Vir Biotechnology, Inc.$VIR | 38.2 | $129.4M | 12,694,163 |
 Maze Therapeutics, Inc.$MAZE | 10.3 | $123.0M | 4,120,053 |
 Lyell Immunopharma, Inc.$LYEL | 9.3 | $45.5M | 3,247,162 |
 Generate Biomedicines, Inc.$GENB | — | $32.8M | 1,944,426 |
 10x Genomics, Inc.$TXG | 40.5 | $8.4M | 217,834 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of ARCH Venture Management, LLC's 12 positions.
Showing top 10 of 12 holdings.
Sector Allocation
Healthcare
$1.1B
Technology
$8.4M
Full Holdings — ARCH Venture Management, LLC (Q2 2026)
All 12 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PBLS | Parabilis Medicines, Inc. | $175.5M | 15.9% | NEW | — |
| 2 | $BEAM | Beam Therapeutics Inc. | $155.8M | 14.2% | +0% | 34.2 |
| 3 | $RAPP | Rapport Therapeutics, Inc. | $155.4M | 14.1% | +0% | — |
| 4 | $SPTX | Seaport Therapeutics, Inc. | $136.6M | 12.4% | NEW | — |
| 5 | $ERAS | Erasca, Inc. | $129.9M | 11.8% | +0% | — |
| 6 | $VIR | Vir Biotechnology, Inc. | $129.4M | 11.8% | -2% | 38.2 |
| 7 | $MAZE | Maze Therapeutics, Inc. | $123.0M | 11.2% | +0% | 10.3 |
| 8 | $LYEL | Lyell Immunopharma, Inc. | $45.5M | 4.1% | +0% | 9.3 |
| 9 | $GENB | Generate Biomedicines, Inc. | $32.8M | 3.0% | +0% | — |
| 10 | $TXG | 10x Genomics, Inc. | $8.4M | 0.8% | +0% | 40.5 |
| 11 |  $BOLD | Boundless Bio, Inc. | $6.7M | 0.6% | NEW | — |
| 12 |  $GOSS | Gossamer Bio, Inc. | $1.3M | 0.1% | +0% | 8.2 |
New Positions (3)
Exited Positions (1)
$FIXX Q32 Bio Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for ARCH Venture Management, LLC including:
Track ARCH Venture Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for ARCH Venture Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: ARCH Venture Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For ARCH Venture Management, LLC (SEC CIK: 1274403), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in ARCH Venture Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.